BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10629629)

  • 1. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
    Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
    Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
    Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory tests for neuroendocrine tumours.
    Seregni E; Ferrari L; Stivanello M; Dogliotti L
    Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A measurement in neuroendocrine tumors.
    Ferrari L; Seregni E; Martinetti A; Van Graafeiland B; Nerini-Molteni S; Botti C; Artale S; Cresta S; Bombardieri E
    Int J Biol Markers; 1998; 13(1):3-9. PubMed ID: 9681293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
    Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
    Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogranin A.
    Hendy GN; Bevan S; Mattei MG; Mouland AJ
    Clin Invest Med; 1995 Feb; 18(1):47-65. PubMed ID: 7768066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in neuroendocrine tumours.
    Oberg K; Janson ET; Eriksson B
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ; Currás Freixes M
    Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different patterns of chromogranin A and Leu-7 (CD57) expression in gastrointestinal carcinoids: immunohistochemical and confocal laser scanning microscopy study.
    Jirásek T; Hozák P; Mandys V
    Neoplasma; 2003; 50(1):1-7. PubMed ID: 12687271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical diagnosis of neuroendocrine GEP tumor.
    Oberg K
    Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chromogranin A in blood--a useful tumor marker].
    Syversen U; Heide LS; Waldum HL
    Tidsskr Nor Laegeforen; 1997 Oct; 117(26):3810-1. PubMed ID: 9417686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha).
    Dirnhofer S; Freund M; Rogatsch H; Krabichler S; Berger P
    Hum Pathol; 2000 Aug; 31(8):966-72. PubMed ID: 10987258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
    J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of elevated serum chromogranin A levels.
    Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
    Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.